Impact of HBV and HCV coinfection on CD4 cells among HIV-infected patients: a longitudinal retrospective study

  • Claudinei Mesquita da Silva Maringá State University, Maringá, Paraná, Brazil
  • Leyde Daiane de Peder Maringá State University, Maringá, Paraná, Brazil
  • Eraldo S Silva State University Maringa, Maringá, Paraná, Brazil
  • Isolde Previdelli State University Maringa, Maringá, Paraná, Brazil
  • Omar Cleo Neves Pereira State University Maringa, Maringá, Paraná, Brazil
  • Jorge Juarez Vieira Teixeira State University Maringa, Maringá, Paraná, Brazil
  • Dennis Armando Bertolini State University Maringa, Maringá, Paraná, Brazil
Keywords: CD4 lymphocyte count, coinfection, HIV, hepatitis B virus, hepatitis C virus

Abstract

Introduction: The impact of hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection on CD4 cells in patients with human immunodeficiency virus (HIV) is unclear. We aimed to examine the impact of HBV and HCV coinfection on CD4 cell count and CD4/CD8 ratio in adults with HIV.

Methodology: We conducted a longitudinal retrospective study in Brazil between January 1, 2002, and June 30, 2016, including 205 patients with HIV monoinfection, 37 with HIV-HBV coinfection, 35 with HIV-HCV coinfection, and 62 with HIV-HCV (48 HCV genotype 1 and 14 HCV genotype 3).

Results: Median duration of follow-up was 2,327 (interquartile range: 1,159–3,319) days. An increased CD4 cell count and CD4/CD8 ratio over time was observed in all groups receiving combined antiretroviral therapy (cART). Patients with HIV-HBV or HIV-HCV coinfection and those with HIV monoinfection, showed comparable CD4 cell counts and CD4/CD8 ratios during pre-ART. There was also no statistically significant difference in CD4/CD8 ratio between HIV-HBV or HIV-HCV coinfection groups and the HIV monoinfection group during follow-up on cART. However, CD4 cell counts were significantly lower in HIV-HCV patients than in HIV monoinfection patients during follow-up on cART. HIV patients with HCV genotype 3 coinfection showed significantly lower CD4/CD8 ratio during follow-up on cART than those coinfected with HCV genotype 1 coinfection. No statistically significant effect of coinfection was observed on the efficacy of cART.

Conclusions: HIV-infected patients are more likely to show better immunological responses to cART when they are not coinfected with HCV.

Published
2018-11-30
How to Cite
1.
Silva C, Peder L, Silva E, Previdelli I, Pereira O, Teixeira JJ, Bertolini D (2018) Impact of HBV and HCV coinfection on CD4 cells among HIV-infected patients: a longitudinal retrospective study. J Infect Dev Ctries 12:1009-1018. doi: https://doi.org/10.3855/jidc.10035
Section
Original Articles